SCHEMBL709795

SCHEMBL709795

Nc1cc(-c2ccccc2)cnc1N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.59
CASP1 P29466 1/20 0.59
MAP4K4 O95819 3/20 0.56
USP7 Q93009 2/20 0.56
GSK3B P49841 4/20 0.51
MKNK1 Q9BUB5 2/20 0.50
CHEK2 O96017 1/20 0.50
FYN P06241 2/20 0.49
PDPK1 O15530 1/20 0.47
CDK1 P06493 1/20 0.47
CDK2 P24941 1/20 0.47
MKNK2 Q9HBH9 1/20 0.47
GSK3A P49840 1/20 0.47
NPC1 O15118 1/20 0.46
NFKB1 P19838 1/20 0.46
RAB9A P51151 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PRKCI P41743 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethylamine SCHEMBL2972047 0.92 MAPT (0.57) MAPTCASP1MAP4K4USP7GSK3B
SCHEMBL712180 0.86 PIK3CD (0.43) MAPTCASP1MAP4K4USP7GSK3B
SCHEMBL971373 0.81 MAP4K4 (0.80) MAP4K4USP7MKNK1CHEK2FYN
SCHEMBL1519413 0.81 AURKA (0.61) MAPTCASP1MAP4K4USP7CHEK2
SCHEMBL15717099 0.81 MAPT (0.58) MAPTCASP1MAP4K4USP7GSK3B
SCHEMBL712179 0.80 FYN (0.58) MAPTCASP1MKNK1CHEK2FYN
SCHEMBL21857207 0.79 MAPT (0.56) MAPTCASP1MAP4K4USP7GSK3B
SCHEMBL14909752 0.79 MAPT (0.61) MAPTCASP1MAP4K4USP7GSK3B
SCHEMBL15910819 0.79 MAPT (0.56) MAPTCASP1MAP4K4USP7GSK3B
SCHEMBL1582343 0.79 MAP4K4 (0.54) MAPTCASP1MAP4K4USP7CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109790148-B Cyano-substituted heterocycles having USP30 inhibitor activity 特殊治疗有限公司 2022-06-07 CN disclosed
EP-3519397-B1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LTD (GB) 2021-05-19 EP disclosed
EP-3519397-B1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LTD (GB) 2021-05-19 EP disclosed
US-10927110-B2 Cyano-subtituted heterocycles with activity as inhibitors of USP30 MISSION THERAPEUTICS LIMITED (GB) 2021-02-23 US disclosed
US-10927110-B2 Cyano-subtituted heterocycles with activity as inhibitors of USP30 MISSION THERAPEUTICS LIMITED (GB) 2021-02-23 US disclosed
CN-108640872-B GSK-3 inhibitor and preparation method and application thereof 山东大学 2020-04-07 CN disclosed
EP-3519397-A1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 Mission Therapeutics Limited (GB) 2019-08-07 EP disclosed
US-20190218215-A1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LIMITED (GB) 2019-07-18 US disclosed
US-20190218215-A1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LIMITED (GB) 2019-07-18 US disclosed
CN-109790148-A Cyano-substituted heterocycles having USP30 inhibitor activity 特殊治疗有限公司 2019-05-21 CN disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
EP-1490366-B1 ALKOXYPYRIDINE-DERIVATIVES NYCOMED GMBH (DE) 2008-01-23 EP disclosed
CN-1307176-C Novel alkoxypyridine derivatives ALTANA PHARMA AG (DE) 2007-03-28 CN disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed
US-7138399-B2 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved ALTANA PHARMA AG (DE) 2006-11-21 US disclosed
US-20050171125-A1 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved ALTANA PHARMA AG (DE) 2005-08-04 US disclosed
CN-1642955-A Novel alkoxypyridine derivatives ALTANA PHARMA AG (DE) 2005-07-20 CN disclosed
EP-1490366-A1 NOVEL ALKOXYPYRIDINE-DERIVATIVES ALTANA Pharma AG (DE) 2004-12-29 EP disclosed
WO-2003080607-A1 NOVEL ALKOXYPYRIDINE-DERIVATIVES ALTANA PHARMA AG (DE) 2003-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218215-A1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 USP30, USP28, USP1 MAPT 3709/4885CASP1 1035/4885MAP4K4 3032/4885
US-10927110-B2 Cyano-subtituted heterocycles with activity as inhibitors of USP30 USP30, USP28, USP1 MAPT 3709/4885CASP1 1035/4885MAP4K4 3032/4885
US-20050171125-A1 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved NOS2, PNP, PTGIS MAPT 4486/4885CASP1 217/4885MAP4K4 1291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.